慢性乙型肝炎病毒携带者血清GP73水平与肝组织病理学变化的关系研究*

doi:10.3969/j.issn.1672-5069.2018.05.016

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎病毒携带者血清高尔基体蛋白73（GP73）水平与肝组织病理学变化的关系。方法 2014年1月~2016年12月我院诊治的慢性HBV携带者150例、慢性乙型肝炎患者150例和乙型肝炎肝硬化患者150例,另选同期健康人50例,采用ELISA法检测GP73水平,对150例慢性HBV携带者进行肝穿刺活检,采用Metavir评分对肝组织炎症和纤维化进行评价。结果慢性HBV携带者血清GP73水平为（46.5±7.8） ng/ml,慢性乙型肝炎组为（90.2±10.9） ng/ml,乙型肝炎肝硬化组为（231.6±20.1） ng/ml,均显著高于健康人组的（36.7±6.6） ng/ml,差异有统计学意义（P<0.05）,肝硬化患者血清GP73水平也显著高于慢性乙型肝炎或HBV携带者（P<0.05）;经肝组织检查,150例慢性HBV携带者肝内炎症活动度分级和纤维化分期表现为G₀~G₁ 105例,G₂30例,G₃~G₄ 15例,其血清GP73水平分别为（45.2±12.8）ng/ml、（63.8±15.0）ng/ml和（83.7±20.1）ng/ml,S₀~S₁ 98例,S₂ 3₀例,S₃~S₄ 22例,其血清GP73水平分别为（45.1±16.8）ng/ml、（67.3±16.4）ng/ml和（72.0±18.4）ng/ml,肝组织炎症活动度分级和纤维化分期严重的患者血清GP73水平显著升高,与分级或分期轻的人群比,差异有统计学意义（F=16.8,F=19.2,P均<0.05）;Logistic回归分析发现血清GP73水平升高是慢性HBV携带者肝组织显著炎症（OR=1.1,95 % CI:1.0~1.1,P<0.05）和显著肝纤维化（OR=2.1,95% CI:0.8~1.2,P<0.05）的高危因素。结论检测血清GP73水平可能有助于对慢性HBV携带者肝组织炎症分级和纤维化分期的判断,能否作为预测慢性HBV携带者肝组织炎症分级和纤维化分期的潜在标志物,还需要扩大验证。

关键词: 慢性乙型肝炎, HBV携带者, 肝组织炎症, 纤维化, 高尔基体蛋白73

Abstract: Objective To forecast hepatic activity index and liver fibrosis staging by serum golgiprotein-73（GP73） levels in individuals with chronic hepatitis B viral carriers. Methods 150 individuals with chronic HBV carriers,150 patients with chronic hepatitis B,150 patients with hepatitis B liver cirrhosis and 50 healthy persons were recruited in this study between January 2014 and December 2016,and serum GP73 levels were detected by ELISA. Liver biopsies were performed in 150 individuals with chronic HBV carriers,and liver inflammation grading and fibrosis staging were evaluated by Metavir score. Results Serum GP73 level in patients with liver cirrhosis was （231.6±20.1） ng/ml,much higher than （46.5±7.8） ng/ml in chronic HBV carrier or （90.2±10.9） ng/ml in patients with chronic hepatitis B,and all of them were higher than（36.7±6.6） ng/ml in healthy persons （P<0.05）;the liver biopsies in individuals with HBV carrier showed that G₀~G₁ were found in 105,G₂ in 30 and G₃~G₄ in 15,and serum GP73 levels were（45.2±12.8）ng/ml,（63.8±15.0）ng/ml and（83.7±20.1）ng/ml,respectively,and S0~S1 in 98,S2 in 30 and S₃~S₄ in 22,and serum GP73 levels were（45.1±16.8）ng/ml,（67.3±16.4）ng/ml and（72.0±18.4）ng/ml,respectively,suggesting obviously increased serum GP73 levels in those with significant liver histopathologic inflammation grading and significant fibrosis staging（F=16.8,F=19.2,P<0.05）;Logistic regression analysis showed that increased serum GP73 level was an independent factor for significant hepatic inflammation （OR=1.1,95% confidence interval:1.0~1.1,P<0.05） and for significant liver fibrosis （OR=2.1,95% CI:0.8~1.2,P<0.05）. Conclusion Serum GP73 level is associated with liver inflammation grade and fibrosis stage in chronic HBV carriers,which warrants further study to determine whether or not it might be acted as an potential marker for predicting liver inflammation and fibrosis.

Key words: Chronic hepatitis B, Hepatitis B viral carrier, Liver histopathology, Golgi protein 73

周志凌, 印倩. 慢性乙型肝炎病毒携带者血清GP73水平与肝组织病理学变化的关系研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 717-720.

Zhou Zhiling, Yin Qian.. Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 717-720.

参考文献

[1] Ott JJ,Stevens GA,Groeger J,et al.Global epidemiology of hepatitis B virus infection:New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30(12):2212-2219.
[2] Lavanchy D.Hepatitis B virus epidemiology,disease burden,treatment,and current and emerging prevention and control measures. J Viral Hepat,2004,11(2):97-103.
[3] Liang X,Bi S,Yang W,et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine,2009,27(47):6550-6557.
[4] Zkan H,Erdal H,Tutkak H,et al.Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion,2011,83(1-2):83-88.
[5] Cao Z,Li Z,Wang H,et al.Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int,2017,37(11):1612-1621.
[6] Hu JS,Wu DW,Liang S,et al.GP73,a resident Golgi glycoprotein,is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol,2010,27(2):339-345.
[7] Yong Q,Chen J,Xin L,et al.Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem,2014,47(16-17):216-222.
[8] Wei H,Li B,Zhang R,et al.Serum GP73,a marker for evaluating progression in patients with chronic HBV infections. Plos One,2013,8(2):e53862.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[10] 郑联坵,魏开鹏,潘兴南,等. 血清高尔基体蛋白73诊断肝细胞癌价值探讨. 实用肝脏病杂志,2013,16(5):407-410.
[11] 陆伟,张占卿,沈芳,等. 血清HBsAg和HBV DNA定量水平预测慢性乙型肝炎患者肝组织炎症活动度和纤维化程度的评价. 实用肝脏病杂志,2016,19(1):20-25.
[12] Liao R,Fu YP,Wang T,et al.Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:a retrospective cohort study at two centers in China. Oncotarget,2017,8(1):1774-1781.
[13] Fu J,Guo D,Gao D,et al.Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses. J Med Virol,2016,88(6):1003-1009.
[14] 何显,曹伟,赵彩彦. 慢性乙型肝炎和肝硬化患者肝组织脂联素及其受体2表达的变化. 实用肝脏病杂志,2013,16(1):50-52.
[15] Eminler AT,Ayyildiz T,Irak K,et al.AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J GastroenterolHepatol,2015,27(12):1361-1366.
[16] Block TM,Comunale MA,Lowman M,et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl AcadSci USA,2005,102(3):779-784.
[17] Chen X,Wang Y,Tao J,et al.mTORC1 Upregulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in cice. Gastroenterology,2015,149(3):741-752.
[18] European Association For The Study Of The Liver. EASL Clinical Practice Guidellines:Management of chronic hepatitis B. J Hepatol,2012,57(1):167-185.
[19] Zheng XU,Pan X,Wei K,et al.Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Mol Med Rep,2015,11(4):2644-2652.
[20] Shan SG,Gao YT,Xu YJ,et al.Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Res,2013,43(11):1199-1210.
[21] Morota K,Nakagawa M,Sekiya R,et al.A comparative evaluation of Golgi protein-73,fucosylatedhemopexin,α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis,and hepatocellular carcinoma. Clin Chem Lab Med,2011,49(4):711-718.
[22] Mao Y,Yang H,Xu H,et al.Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut,2010,59(12):1687-1693.

慢性乙型肝炎病毒携带者血清GP73水平与肝组织病理学变化的关系研究^*

Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[14]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[15]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.